A Real-World Analysis of the Clinical Journey, Diagnosis, and Monitoring Patterns of Patients With Alzheimer Disease by Stage in the United States.

Abstract

This study aimed to describe the clinical journey of patients with different stages of Alzheimer disease (AD). This was a cross-sectional survey of US primary care physicians (PCPs)/specialists and patients using the Adelphi Real World AD Disease Specific Programme™ (December 2022 - September 2023). Patients were stratified by disease severity and data are presented as the mean (SD) or frequencies/percentages. In the overall sample (N = 990), mean time from symptom onset to first evaluation was 31.4 (40.6) weeks and mean time from evaluation to diagnosis was 14.2 (29.0) weeks (mild cognitive impairment due to AD, 12.0 [22.7] weeks; mild AD dementia, 15.7 [31.6] weeks; moderate AD dementia, 14.0 [29.9] weeks; severe AD dementia, 5.1 [9.6] weeks). 74.5% of the overall sample was initially evaluated by their PCP and 13.8% by a neurologist. Patients with AD experience many barriers during the diagnostic journey; however, PCPs and neurologists play key roles in early diagnosis.